2016 American Transplant Congress
Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV).
Aurora St Luke's Medical Center, Milwaukee, WI.
Background: Current guidelines recommend newer therapies over previous interferon-based treatments. The creation of a specialty pharmacy program within our institution that provides managed care for…2016 American Transplant Congress
Induction Immunosuppression and Post-Transplant Outcomes in Kidney Recipients with Hepatitis C Virus.
Kidney transplantation is a well-established treatment option for ESRD patients with Hepatitis C virus (HCV). However, the optimal induction regimen for this population is uncertain,…2016 American Transplant Congress
HCV, Acute Rejection, and the New Direct-Acting Antivirals in Deceased Donor Kidney Transplant Recipients.
The association between hepatitis C virus (HCV) seropositivity and acute rejection (AR) in kidney transplant donors and recipients is unclear, and may have changed with…2016 American Transplant Congress
Initial Experience Treating Hepatitis C Positive Kidney Transplant Recipients with Non-Interferon-Containing Regimens: Successes and Challenges.
Weill Cornell Medical College, New York, NY.
Historically, treatment of hepatitis C virus (HCV) infection with interferon-based regimens after kidney transplantation has been associated with risk of rejection & graft loss. Direct…2015 American Transplant Congress
Combined Hepatitic/Cholangiopathic Lesion in HIV-HCV Co-Infected Liver Transplant Recipients Associated With Graft Loss
Background: Co-infection with HIV and viral hepatitis results in poorer outcomes following liver transplantation. In this population, complex immune status, extensive drug regimens, and comorbid…2015 American Transplant Congress
Interferon-Free Sofosvir/Ribavirin Treatment Achieves Excellent Sustained Viral Response in Post Liver Transplant HCV Recipients
Purpose: HCV is the leading cause of end-stage liver disease, universally recurring in the post-transplant setting. Studies have shown disappointing results after first generation protease…2015 American Transplant Congress
HCV Treatment in Liver Transplantation: Changes in Center Attitudes and Practices in the DAA Era
Surgery, Johns Hopkins University, Baltimore, MD.
Chronic hepatitis C virus infection (HCV) is the leading indication for liver transplantation (LT) in the US. Safe and effective directly acting antivirals (DAAs) are…2015 American Transplant Congress
Efficacy of Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation
Purpose: Evaluate outcomes of sofosbuvir-based hepatitis C therapy in liver transplant patients in a single center clinical setting, including interferon-free regimens.Methods: All patients with history…2015 American Transplant Congress
Outcomes of Hepatitis C Virus (HCV) Treatment Following Liver Transplantation in the Era of Direct-Acting Antiviral Medications
BACKGROUND: The treatment of HCV is one of the most rapidly changing areas of medical practice. These agents have been shown to be safe and…2015 American Transplant Congress
High Tolerability With Sofosbuvir-Based Direct-Acting Antiviral Therapy in Liver Transplant Recipients With Recurrent Hepatitis C
Background: Reports on efficacy, safety, and tolerability of sofobuvir-based antiviral regimens in liver transplant recipients with recurrent hepatitis C are limited. Methods: We performed a…
American Transplant Congress abstracts